Friday, July 10, 2026

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini

France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
66
Patents
0
Clinical program

CYD32

Phase 3 · mab · Dengue Fever

CYD32 for Dengue Fever is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

← All Sanofi Pasteur projects Phase 3 mab completed

Internal code CYD32

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sanofi Pasteur
Phase
Phase 3
Modality
mab
Indication
Dengue Fever
Status
completed
Trials
1